'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?

P. Muratori, L. Muratori, M. Eric Gershwin, A. J. Czaja, G. Pappas, S. Maccariello, A. Granito, F. Cassani, P. Loria, M. Lenzi, F. B. Bianchi

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Anti-mitochondrial antibody (AMA) is considered the serological hallmark of primary biliary cirrhosis (PBC), but may be missing in a proportion of these patients. We assessed sensitivity and specificity of the currently available techniques for AMA detection in a large series of PBC patients and controls, and analysed their clinical and immunological features according to the AMA status. By indirect immunofluorescence on rat tissue sections and HEp-2 cells, Western immunoblot with bovine submitochondrial particles, and two ELISAs with AMA-specific recombinant proteins, we evaluated the presence of AMA in 127 PBC patients, 166 patients with type 1 autoimmune hepatitis and 100 with non alcoholic fatty liver disease. In PBC patients Western immunoblot detects AMA significantly more often than indirect immunofluorescence on HEp-2 cells (85% versus 72%, P = 0.02) or rodent tissue sections (71%, P = 0.01); both ELISAs are only slightly less sensitive than Western immunoblot (81% and 78%). Ten patients with non alcoholic fatty liver disease were AMA-positive by indirect immunofluorescence, but none recognized AMA-specific epitopes in Western immunoblot or in ELISAs. Twelve patients with type 1 autoimmune hepatitis were AMA-positive by indirect immunofluorescence, but only 6 (3.6%) reacted by Western immunoblot and ELISAs. Western immunoblot or ELISA should be regarded as first-line assay for the detection of AMA. Up to 15% of PBC patients are consistently AMA-negative, yet they share the same clinical, biochemical and histological features of AMA-positive PBC. Detection of AMA in type 1 autoimmune hepatitis might identify a subset of patients at risk of developing a hepatitic/cholestatic syndrome.

Original languageEnglish (US)
Pages (from-to)154-158
Number of pages5
JournalClinical and Experimental Immunology
Volume135
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Biliary Liver Cirrhosis
Anti-Idiotypic Antibodies
Antibodies
Western Blotting
Indirect Fluorescent Antibody Technique
Autoimmune Hepatitis
Enzyme-Linked Immunosorbent Assay
Submitochondrial Particles
Recombinant Proteins
Epitopes
Rodentia

Keywords

  • Autoantibodies
  • Cholestasis
  • Liver
  • Overlap syndrome
  • Western immunoblotting

ASJC Scopus subject areas

  • Immunology

Cite this

'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? / Muratori, P.; Muratori, L.; Gershwin, M. Eric; Czaja, A. J.; Pappas, G.; Maccariello, S.; Granito, A.; Cassani, F.; Loria, P.; Lenzi, M.; Bianchi, F. B.

In: Clinical and Experimental Immunology, Vol. 135, No. 1, 01.2004, p. 154-158.

Research output: Contribution to journalArticle

Muratori, P, Muratori, L, Gershwin, ME, Czaja, AJ, Pappas, G, Maccariello, S, Granito, A, Cassani, F, Loria, P, Lenzi, M & Bianchi, FB 2004, ''True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?', Clinical and Experimental Immunology, vol. 135, no. 1, pp. 154-158. https://doi.org/10.1111/j.1365-2249.2004.02332.x
Muratori, P. ; Muratori, L. ; Gershwin, M. Eric ; Czaja, A. J. ; Pappas, G. ; Maccariello, S. ; Granito, A. ; Cassani, F. ; Loria, P. ; Lenzi, M. ; Bianchi, F. B. / 'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?. In: Clinical and Experimental Immunology. 2004 ; Vol. 135, No. 1. pp. 154-158.
@article{620f455127fc45998463f35a7a82240b,
title = "'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?",
abstract = "Anti-mitochondrial antibody (AMA) is considered the serological hallmark of primary biliary cirrhosis (PBC), but may be missing in a proportion of these patients. We assessed sensitivity and specificity of the currently available techniques for AMA detection in a large series of PBC patients and controls, and analysed their clinical and immunological features according to the AMA status. By indirect immunofluorescence on rat tissue sections and HEp-2 cells, Western immunoblot with bovine submitochondrial particles, and two ELISAs with AMA-specific recombinant proteins, we evaluated the presence of AMA in 127 PBC patients, 166 patients with type 1 autoimmune hepatitis and 100 with non alcoholic fatty liver disease. In PBC patients Western immunoblot detects AMA significantly more often than indirect immunofluorescence on HEp-2 cells (85{\%} versus 72{\%}, P = 0.02) or rodent tissue sections (71{\%}, P = 0.01); both ELISAs are only slightly less sensitive than Western immunoblot (81{\%} and 78{\%}). Ten patients with non alcoholic fatty liver disease were AMA-positive by indirect immunofluorescence, but none recognized AMA-specific epitopes in Western immunoblot or in ELISAs. Twelve patients with type 1 autoimmune hepatitis were AMA-positive by indirect immunofluorescence, but only 6 (3.6{\%}) reacted by Western immunoblot and ELISAs. Western immunoblot or ELISA should be regarded as first-line assay for the detection of AMA. Up to 15{\%} of PBC patients are consistently AMA-negative, yet they share the same clinical, biochemical and histological features of AMA-positive PBC. Detection of AMA in type 1 autoimmune hepatitis might identify a subset of patients at risk of developing a hepatitic/cholestatic syndrome.",
keywords = "Autoantibodies, Cholestasis, Liver, Overlap syndrome, Western immunoblotting",
author = "P. Muratori and L. Muratori and Gershwin, {M. Eric} and Czaja, {A. J.} and G. Pappas and S. Maccariello and A. Granito and F. Cassani and P. Loria and M. Lenzi and Bianchi, {F. B.}",
year = "2004",
month = "1",
doi = "10.1111/j.1365-2249.2004.02332.x",
language = "English (US)",
volume = "135",
pages = "154--158",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - 'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?

AU - Muratori, P.

AU - Muratori, L.

AU - Gershwin, M. Eric

AU - Czaja, A. J.

AU - Pappas, G.

AU - Maccariello, S.

AU - Granito, A.

AU - Cassani, F.

AU - Loria, P.

AU - Lenzi, M.

AU - Bianchi, F. B.

PY - 2004/1

Y1 - 2004/1

N2 - Anti-mitochondrial antibody (AMA) is considered the serological hallmark of primary biliary cirrhosis (PBC), but may be missing in a proportion of these patients. We assessed sensitivity and specificity of the currently available techniques for AMA detection in a large series of PBC patients and controls, and analysed their clinical and immunological features according to the AMA status. By indirect immunofluorescence on rat tissue sections and HEp-2 cells, Western immunoblot with bovine submitochondrial particles, and two ELISAs with AMA-specific recombinant proteins, we evaluated the presence of AMA in 127 PBC patients, 166 patients with type 1 autoimmune hepatitis and 100 with non alcoholic fatty liver disease. In PBC patients Western immunoblot detects AMA significantly more often than indirect immunofluorescence on HEp-2 cells (85% versus 72%, P = 0.02) or rodent tissue sections (71%, P = 0.01); both ELISAs are only slightly less sensitive than Western immunoblot (81% and 78%). Ten patients with non alcoholic fatty liver disease were AMA-positive by indirect immunofluorescence, but none recognized AMA-specific epitopes in Western immunoblot or in ELISAs. Twelve patients with type 1 autoimmune hepatitis were AMA-positive by indirect immunofluorescence, but only 6 (3.6%) reacted by Western immunoblot and ELISAs. Western immunoblot or ELISA should be regarded as first-line assay for the detection of AMA. Up to 15% of PBC patients are consistently AMA-negative, yet they share the same clinical, biochemical and histological features of AMA-positive PBC. Detection of AMA in type 1 autoimmune hepatitis might identify a subset of patients at risk of developing a hepatitic/cholestatic syndrome.

AB - Anti-mitochondrial antibody (AMA) is considered the serological hallmark of primary biliary cirrhosis (PBC), but may be missing in a proportion of these patients. We assessed sensitivity and specificity of the currently available techniques for AMA detection in a large series of PBC patients and controls, and analysed their clinical and immunological features according to the AMA status. By indirect immunofluorescence on rat tissue sections and HEp-2 cells, Western immunoblot with bovine submitochondrial particles, and two ELISAs with AMA-specific recombinant proteins, we evaluated the presence of AMA in 127 PBC patients, 166 patients with type 1 autoimmune hepatitis and 100 with non alcoholic fatty liver disease. In PBC patients Western immunoblot detects AMA significantly more often than indirect immunofluorescence on HEp-2 cells (85% versus 72%, P = 0.02) or rodent tissue sections (71%, P = 0.01); both ELISAs are only slightly less sensitive than Western immunoblot (81% and 78%). Ten patients with non alcoholic fatty liver disease were AMA-positive by indirect immunofluorescence, but none recognized AMA-specific epitopes in Western immunoblot or in ELISAs. Twelve patients with type 1 autoimmune hepatitis were AMA-positive by indirect immunofluorescence, but only 6 (3.6%) reacted by Western immunoblot and ELISAs. Western immunoblot or ELISA should be regarded as first-line assay for the detection of AMA. Up to 15% of PBC patients are consistently AMA-negative, yet they share the same clinical, biochemical and histological features of AMA-positive PBC. Detection of AMA in type 1 autoimmune hepatitis might identify a subset of patients at risk of developing a hepatitic/cholestatic syndrome.

KW - Autoantibodies

KW - Cholestasis

KW - Liver

KW - Overlap syndrome

KW - Western immunoblotting

UR - http://www.scopus.com/inward/record.url?scp=9144261236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144261236&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2249.2004.02332.x

DO - 10.1111/j.1365-2249.2004.02332.x

M3 - Article

C2 - 14678277

AN - SCOPUS:9144261236

VL - 135

SP - 154

EP - 158

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 1

ER -